Cargando…
Anti-obesity drug discovery: advances and challenges
Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity...
Autores principales: | Müller, Timo D., Blüher, Matthias, Tschöp, Matthias H., DiMarchi, Richard D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609996/ https://www.ncbi.nlm.nih.gov/pubmed/34815532 http://dx.doi.org/10.1038/s41573-021-00337-8 |
Ejemplares similares
-
GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017) -
Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity: The Case for Personalized Combinatorial Therapies
por: Tschöp, Matthias H., et al.
Publicado: (2012) -
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
por: Jall, Sigrid, et al.
Publicado: (2017) -
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
por: Capozzi, Megan E, et al.
Publicado: (2018) -
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
por: Tan, Qiming, et al.
Publicado: (2022)